There are currently 93 active clinical trials seeking participants for Sickle Cell Disease research studies. The states with the highest number of trials for Sickle Cell Disease participants are New York, North Carolina, California and Georgia.
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT05477563
Recruiting
This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) using CTX001.
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
03/28/2025
Locations: Columbia University Medical Center, New York, New York +5 locations
Conditions: Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Hemoglobinopathies, Sickle Cell Anemia, Sickle Cell Disease
Register for Updates
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04398628
Recruiting
In parallel with the growth of American Thrombosis and Hemostasis Network's (ATHN) clinical studies, the number of new therapies for all congenital and acquired hematologic conditions, not just those for bleeding and clotting disorders, is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have yet to demonstrate long-term safety and effectiveness beyond the pivotal trials that led to their approval. In addition, results from... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/26/2025
Locations: Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital, Phoenix, Arizona +72 locations
Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Register for Updates
Gene Editing For Sickle Cell Disease
NCT06506461
Recruiting
This study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and help reduce the symptoms of SCD. Primary Objective * To assess the safety of autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoieti... Read More
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
03/24/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Sickle Cell Disease
Register for Updates
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
NCT05730205
Recruiting
The objective of this study is to measure the acceptability and impact of the progestin implant on frequency of vaso-occlusive crises, quality of life, and hematologic parameters in women with SCD.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
03/24/2025
Locations: Penn Medicine University City, Philadelphia, Pennsylvania
Conditions: Sickle Cell Disease
Register for Updates
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).
Gender:
ALL
Ages:
Between 12 years and 55 years
Trial Updated:
03/10/2025
Locations: Quotient Sciences Sea View, Miami, Florida
Conditions: Sickle Cell Disease
Register for Updates
Allo HSCT for High Risk Hemoglobinopathies
NCT06872333
Recruiting
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
Gender:
ALL
Ages:
55 years and below
Trial Updated:
03/06/2025
Locations: Masonic Cancer Center, Minneapolis, Minnesota
Conditions: Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Register for Updates
Cognitive Remediation Intervention to Prepare for Transition of Care
NCT05336201
Recruiting
Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to prepare adolescents with sickle cell disease for transition of care.
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
02/28/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Sickle Cell Disease, Cognitive Impairment, Adolescent Behavior, Self Efficacy, Health-Related Behavior, Coping Skills
Register for Updates
Sickle Cell Clinical Research and Intervention Program
NCT02098863
Recruiting
Despite the important work of previous sickle cell disease (SCD) cohort studies, there remain many understudied areas that require investigation. An important knowledge deficit is the slow but progressive process of chronic end-organ dysfunction. The majority of organ dysfunction becomes apparent in the young adult years, but comprehensive assessment of adults and understanding of predictors of adulthood organ dysfunction are insufficient. Similarly, the role of disease-modifying therapies, such... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/25/2025
Locations: Children's Hospital of Illinois at OSF-Saint Francis Medical Center, Peoria, Illinois +5 locations
Conditions: Sickle Cell Disease
Register for Updates
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
NCT03353584
Recruiting
Acute vaso-occlusive crisis (VOC) is the most common complication in patients with sickle cell disease (SCD) and pain related to VOC is often inadequately treated. This is a phase II randomized controlled clinical trial evaluating the efficacy of virtual reality technology when added to standard pain management for patients with sickle cell disease who are experiencing acute pain crisis in the ambulatory care setting. Patients will be randomized to receive either standard management only or stan... Read More
Gender:
ALL
Ages:
Between 6 years and 25 years
Trial Updated:
02/25/2025
Locations: Methodist Comprehensive Sickle Cell Center, Memphis, Tennessee +1 locations
Conditions: Sickle Cell Disease, Vaso-occlusive Crisis
Register for Updates
Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease
NCT05758766
Recruiting
Sickle cell disease (SCD) is associated with significant morbidity and mortality. Pain and many adverse outcomes occurring in sickle cell disease are inflammatory driven. Recent data has shown that gut dysbiosis is present in individuals with sickle cell disease. Gut dysbiosis has been linked to inflammation in certain diseases. Omega -3-fatty acids (fish oil) has been shown to improve pain outcomes in individuals with sickle cell disease, but its acceptance is variable. The aim of this study is... Read More
Gender:
ALL
Ages:
Between 5 years and 18 years
Trial Updated:
02/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Sickle Cell Disease
Register for Updates
Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease
NCT06770010
Recruiting
This is a single site nonrandomized pilot clinical trial of the feasibility, acceptability, and efficacy of a combination treatment involving digital Cogmed working memory skills training, social support components, and memory strategy training to improve adherence to Cogmed in youth with sickle cell disease ages 7-16 years.
Gender:
ALL
Ages:
Between 7 years and 16 years
Trial Updated:
02/12/2025
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Sickle Cell Disease
Register for Updates
Integrative Medicine in Pain Management in Sickle Cell Disease
NCT05045820
Recruiting
The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.
Gender:
ALL
Ages:
Between 14 years and 80 years
Trial Updated:
02/03/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Sickle Cell Disease, Pain, Acupuncture, Quantitative Sensory Testing, Magnetic Resonance Imaging, Circulating Biomarkers, Electroencephalography, Functional Near-infrared Spectroscopy
Register for Updates